Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated by Analysts at William Blair

Stock analysts at William Blair began coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a report released on Monday. The brokerage set an “outperform” rating on the stock.

Several other research firms have also weighed in on EPRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. HC Wainwright dropped their target price on Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Zacks Research lowered shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. Finally, Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Eupraxia Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Price Performance

EPRX stock opened at $7.10 on Monday. The firm has a market capitalization of $255.32 million, a P/E ratio of -6.89 and a beta of 1.27. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $9.32. The company’s 50 day simple moving average is $8.26 and its 200-day simple moving average is $6.91.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.21). Sell-side analysts predict that Eupraxia Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in EPRX. Vivo Capital LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at approximately $7,965,000. Ally Bridge Group NY LLC bought a new position in Eupraxia Pharmaceuticals during the third quarter valued at approximately $5,398,000. Ikarian Capital LLC bought a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $4,606,000. Squadron Capital Management LLC acquired a new stake in Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $3,775,000. Finally, Velan Capital Investment Management LP bought a new stake in Eupraxia Pharmaceuticals in the third quarter worth approximately $2,077,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.